Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Rasmussen

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|February 13, 2023
Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4Katie Fisher, Timothy E Schlub, Zoe Boyer, et al.
Journal of Virology|February 4, 2025
Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoirRachel D Pascoe, Youry Kim, Ajantha Rhodes, et al.
Frontiers in Immunology|April 14, 2023
Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapyChris Y Chiu, Maya D Schou, James H McMahon, et al.
Plos Pathogens|August 26, 2016
Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 DaysMykola Pinkevych, Stephen J Kent, Martin Tolstrup, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2015
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infectionsKasper L Jønsson, Martin Tolstrup, Johan Vad-Nielsen, et al.
Plos Pathogens|August 26, 2016
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Plos Pathogens|July 3, 2015
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Mediators of Inflammation|December 24, 2015
Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 PatientsAne Bjerg Christensen, Anders Dige, Johan Vad-Nielsen, et al.
Journal of Virology|July 31, 2015
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with PanobinostatRikke Olesen, Selena Vigano, Thomas A Rasmussen, et al.
The Lancet. HIV|October 2, 2015
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trialThomas A Rasmussen, Martin Tolstrup, Christel R Brinkmann, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|February 13, 2023
Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4Katie Fisher, Timothy E Schlub, Zoe Boyer, et al.
Journal of Virology|February 4, 2025
Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoirRachel D Pascoe, Youry Kim, Ajantha Rhodes, et al.
Frontiers in Immunology|April 14, 2023
Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapyChris Y Chiu, Maya D Schou, James H McMahon, et al.
Plos Pathogens|August 26, 2016
Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 DaysMykola Pinkevych, Stephen J Kent, Martin Tolstrup, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2015
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infectionsKasper L Jønsson, Martin Tolstrup, Johan Vad-Nielsen, et al.
Plos Pathogens|August 26, 2016
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Plos Pathogens|July 3, 2015
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV RemissionMykola Pinkevych, Deborah Cromer, Martin Tolstrup, et al.
Mediators of Inflammation|December 24, 2015
Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 PatientsAne Bjerg Christensen, Anders Dige, Johan Vad-Nielsen, et al.
Journal of Virology|July 31, 2015
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with PanobinostatRikke Olesen, Selena Vigano, Thomas A Rasmussen, et al.
The Lancet. HIV|October 2, 2015
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trialThomas A Rasmussen, Martin Tolstrup, Christel R Brinkmann, et al.
Pageof 7